Covered recipient · General Payments record
RONALD W KENNETT
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2019–2025
$2,611.76
- Reported across 140 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $336.10 | 16 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $106.20 | 5 |
| Novo Nordisk AS | $82.47 | 4 |
| Medtronic, Inc. | $39.89 | 2 |
| ABBVIE INC. | $28.87 | 1 |
| Lilly USA, LLC | $27.81 | 2 |
| EISAI INC. | $25.71 | 1 |
| Corcept Therapeutics | $25.15 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $28.87 | 02/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1202179991 | CMS |
| Corcept Therapeutics | $25.15 | 06/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1214140709 | CMS |
| Eisai Inc. | $25.71 | 01/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1244509545 | CMS |
| GlaxoSmithKline, LLC. | $19.92 | 01/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190739608 | CMS |
| GlaxoSmithKline, LLC. | $21.05 | 02/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190601485 | CMS |
| GlaxoSmithKline, LLC. | $17.50 | 02/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1191246283 | CMS |
| GlaxoSmithKline, LLC. | $28.31 | 03/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1191005103 | CMS |
| GlaxoSmithKline, LLC. | $19.42 | 04/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190859050 | CMS |
| Lilly USA, LLC | $13.71 | 03/23/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186899025 | CMS |
| Lilly USA, LLC | $14.10 | 08/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186936892 | CMS |
| Medtronic, Inc. | $17.01 | 09/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1219941484 | CMS |
| Medtronic, Inc. | $22.88 | 10/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1219941486 | CMS |
| Novo Nordisk Inc | $27.51 | 05/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188488789 | CMS |
| Novo Nordisk Inc | $17.28 | 05/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188336362 | CMS |
| Novo Nordisk Inc | $21.23 | 07/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188607662 | CMS |
| Novo Nordisk Inc | $16.45 | 07/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188839665 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.